Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Imaging Studies IV: Magnetic Resonance Imaging

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

B7-H4-targeted radiotheranostics enable precise imaging and potent therapy across solid tumor models.

Science advances·2026

Same author

Development and validation of a multimodal artificial intelligence-based model for predicting post-prostatectomy treatment outcomes from baseline biparametric prostate magnetic resonance imaging.

Diagnostic and interventional radiology (Ankara, Turkey)·2026

Same author

Ablation of glypican-3 enhances radiosensitivity in liver cancer by prolonging G2/M arrest and activating the ATM/CHK2 pathway.

bioRxiv : the preprint server for biology·2026

Same author

<i>Ad-verse Effects:</i> Pharmaceutical Advertising Shifts Drug Recommendations by Consumer-Facing AI.

medRxiv : the preprint server for health sciences·2026

Same author

OncoBERT: Context-Aware Modeling of Somatic Mutations for Precision Oncology.

bioRxiv : the preprint server for biology·2026

Same author

Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.

Nature medicine·2026

Search research articles

Related Experiment Video

Updated: Dec 14, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Novel PET imaging methods for prostate cancer.

Esther Mena¹, Peter C Black², Soroush Rais-Bahrami³

¹Molecular Imaging Program, National Cancer Institute, 10 Center Dr, Bldg 10, Room B3B69F, Bethesda, MD, 20892-1088, USA.

World Journal of Urology

|July 17, 2020

Summary

Prostate-specific membrane antigen (PSMA) PET imaging is a leading advancement for prostate cancer diagnosis. This advanced PET agent offers superior sensitivity and specificity compared to conventional methods.

Keywords:

Biochemical recurrence Molecular imaging Prostate cancer Prostate-specific membrane antigen Staging

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Dec 14, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

Area of Science:

Nuclear Medicine
Oncology
Radiochemistry

Background:

Prostate cancer is a prevalent malignancy.
Conventional imaging (CT, bone scan) often lacks sensitivity for prostate cancer detection.
Emerging positron emission tomography (PET) agents offer improved diagnostic capabilities.

Purpose of the Study:

To review the literature on PET imaging agents for prostate cancer.
To identify the most effective PET agents for diagnosing and managing prostate cancer.

Main Methods:

Comprehensive literature search on PET imaging agents for prostate cancer.
Analysis of agent sensitivity and specificity.

Main Results:

A variety of PET imaging agents were identified.
Prostate-specific membrane antigen (PSMA) PET demonstrated superior performance.
Other agents exhibited limitations in sensitivity or specificity compared to PSMA PET.

Conclusions:

PSMA PET has emerged as the premier imaging agent for prostate cancer.
PSMA PET is expected to significantly impact prostate cancer diagnosis, staging, and patient management.